The grant was awarded by the Bill & Melinda Gates Foundation for the development of a breakthrough vaccine manufacturing platform with the objective of radically lowering costs and increasing vaccine availability and affordability in developing countries.
Picture: Hugues Bultot, José Castillo and Paul Magnette. Source: ALA
“As a result, we expect our integrated platform to be a real game-changer for global health,” claims José Castillo, CTO and co-founder of Univercells.
Univercells, the Belgian biotech company founded in 2013, will form a consortium with Batavia Biosciences and Natrix Separations in order to execute the development of the platform that integrates continuous processing with extremely high process intensification. The goal of this collaboration is to create a micro-facility for inactivated polio vaccine (sIPV) that will produce 40 million doses of trivalent vaccine per year at a manufacturing cost of less than $0.15 per dose.
Indeed, vaccines are a powerful contributor to the improvement of global health and a substantial reduction in the cost of manufacturing vaccines could help enable affordable, equitable and sustainable immunization on a global scale.